The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
CV

ca.vermeulen

TL2 Moderator · Monterrey

Contributes reviews on supplier material. Based in Monterrey.

Joined 20 November 2024 · last posted 10h

86Posts here
0Topics
1Solutions
1kLikes received
428Likes given
19Badges
176Days visited
3kPosts read

Most-liked posts

  • Interim analyses and stopping rules Replied, post #10 · Evidence › Trials · 16 Jan 2026 · 33 likes Dropout is information: high dropout rates can indicate tolerability problems or lower efficacy than the summary suggests. Where the analysis handled dropouts matters.…
  • Injecting into an area that has become firm: why not to Replied, post #61 · Practice › Administration · 13 Jun 2026 · 32 likes Injection discomfort: comes from needle gauge (finer = less discomfort), volume (smaller = less discomfort), temperature (room temperature or warmed is less…
  • A parcel that arrived warm: a decision process, not a verdict Replied, post #126 · Practice › Storage & stability · 7 Nov 2025 · 30 likes Coming back to post #124, because the follow-up matters more than the original answer. Having read the exchange above, I think I was wrong earlier in this topic and I…
  • Promotion criteria, and the one that stops most nominations — the long version Replied, post #48 · Documentation › Doc review · 28 Aug 2025 · 30 likes Revision disputes: if you disagree with an edit a maintainer made to a page, discuss it here. The goal is accuracy and clarity, not authorship.
  • Second pass at: Pen dose counters: what a click does and does not guarantee Replied, post #36 · Devices › Pens & autoinjectors · 9 May 2025 · 29 likes Storage after first use: most pens can be stored at room temperature after first use, even if unrefrigerated, for a limited time (often 28 days). Check your specific…
  • Retatrutide dose escalation in the published trials Replied, post #129 · Compounds › Retatrutide · 14 Apr 2025 · 29 likes I read post #127 twice before replying, because I had assumed the opposite. Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist.…

Where this member posts

CategoryPostsShare
Practice1720%
Analytics1113%
Evidence1012%
Compounds89%
Start Here56%
Sourcing56%

Badges earned, in order

BadgeTierGranted
Basic Userbronze22 Nov 2024
Read the Guidelinesbronze24 Nov 2024
First Replybronze27 Nov 2024
First Linkbronze2 Dec 2024
Welcomebronze9 Dec 2024
First Quotebronze9 Dec 2024
Asked Wellbronze13 Dec 2024
Sourcedbronze16 Dec 2024
Generousbronze29 Dec 2024
Memberbronze1 Jan 2025
First Tagbronze16 Jan 2025
First Solutionbronze16 Jan 2025
Editorbronze18 Feb 2025
Readerbronze1 Mar 2025
Good Postsilver11 Mar 2025
Thank Yousilver30 Apr 2025
Nice Postbronze4 May 2025
Anniversarysilver20 Nov 2025
De-escalatorgold25 Dec 2025